Patents by Inventor Jerome Zeldis

Jerome Zeldis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10682336
    Abstract: Methods of treating immune reconstitution inflammatory syndrome (IRIS) in immunodeficient patients, including HIV patients, using PDE4 modulators are described.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 16, 2020
    Assignee: AMGEN INC.
    Inventors: Vikram Khetani, Jerome Zeldis
  • Publication number: 20180318257
    Abstract: Methods of treating immune reconstitution inflammatory syndrome (IRIS) in immunodeficient patients, including HIV patients, using PDE4 modulators are described.
    Type: Application
    Filed: October 20, 2016
    Publication date: November 8, 2018
    Inventors: Vikram Khetani, Jerome Zeldis
  • Publication number: 20080096952
    Abstract: Methods and compositions for the prevention and treatment of all forms of atherosclerosis are described. Administration of compounds such as thalidomide, its analogs, hydrolysis products, metabolites, derivatives and precursors as well as additional compounds capable of inhibiting tumor necrosis factor ? (TNF-?) are used in the invention. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.
    Type: Application
    Filed: December 7, 2007
    Publication date: April 24, 2008
    Inventor: Jerome Zeldis
  • Publication number: 20080038263
    Abstract: Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: August 1, 2007
    Publication date: February 14, 2008
    Inventor: Jerome Zeldis
  • Publication number: 20070299020
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: July 27, 2007
    Publication date: December 27, 2007
    Inventor: Jerome Zeldis
  • Publication number: 20070270448
    Abstract: Methods for treating, preventing and/or managing an asbestos-related disease or disorder are disclosed. Specific embodiments encompass the administration of a JNK Inhibitor, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or chemotherapy, surgery, or radiation therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: November 4, 2004
    Publication date: November 22, 2007
    Applicant: CELGENE CORPORATION
    Inventor: Jerome Zeldis
  • Publication number: 20070244078
    Abstract: Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: April 23, 2004
    Publication date: October 18, 2007
    Inventors: Jerome Zeldis, Herbert Faleck, Donald Manning
  • Publication number: 20070207121
    Abstract: Methods of treating, preventing and/or managing macular degeneration are disclosed. Specific embodiments encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: April 28, 2004
    Publication date: September 6, 2007
    Inventor: Jerome Zeldis
  • Publication number: 20070208057
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of thalidomide alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of thalidomide. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: November 4, 2004
    Publication date: September 6, 2007
    Inventor: Jerome Zeldis
  • Publication number: 20070196330
    Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: January 16, 2007
    Publication date: August 23, 2007
    Inventor: Jerome Zeldis
  • Publication number: 20070190070
    Abstract: Methods of treating, preventing and/or managing central nervous system disorders, such as Parkinson disease, Alzheimer disease, mild cognitive impairment, Huntington disease, Amytophic Lateral Sclerosis, depression and defective long-term memory, and related syndromes are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: September 3, 2004
    Publication date: August 16, 2007
    Inventors: Jerome Zeldis, Peter Schafer
  • Publication number: 20070161696
    Abstract: Methods of treating, preventing, modifying and managing various types of pain are disclosed. Specific methods comprise the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent and/or surgery, psychological or physical therapy. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: April 23, 2004
    Publication date: July 12, 2007
    Inventors: Jerome Zeldis, Herbert Faleck, Donald Manning
  • Publication number: 20070155791
    Abstract: Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione (ACTIMID™), 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (REVLIMID®), or cyclopropyl 2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin-4-yl}carboxamide, alone or alternatively, in combination with a second active agent.
    Type: Application
    Filed: December 21, 2006
    Publication date: July 5, 2007
    Inventors: Jerome Zeldis, Patricia Rohane, Peter Schafer
  • Publication number: 20060270707
    Abstract: Methods of treating, managing or preventing cutaneous lupus are disclosed. Specific methods encompass the administration of 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione alone or in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms are also disclosed.
    Type: Application
    Filed: May 16, 2006
    Publication date: November 30, 2006
    Inventors: Jerome Zeldis, Patricia Rohane, Peter Schafer
  • Publication number: 20060199843
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: November 6, 2003
    Publication date: September 7, 2006
    Inventor: Jerome Zeldis
  • Publication number: 20060183774
    Abstract: In one aspect, the present invention is directed to methods for treating fatigue, neurobehavioral slowing and other cognitive disorders and defects due to cancers and treatments associated with cancers, and similar conditions. In a further aspect, the present invention is directed to methods for treating disorders related to menopause, including executive function defects. The methods involve the administration of a composition comprising D-threo methylphenidate that is substantially free of L-threo methylphenidate and of erythro forms of methylphenidate.
    Type: Application
    Filed: April 11, 2006
    Publication date: August 17, 2006
    Inventors: Jerome Zeldis, Andrew Zeitlin, Herbert Faleck, Vikram Khetani, Maghsoud Dariani, David Sterling
  • Publication number: 20060172970
    Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: March 7, 2006
    Publication date: August 3, 2006
    Inventor: Jerome Zeldis
  • Publication number: 20060166932
    Abstract: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: March 8, 2006
    Publication date: July 27, 2006
    Inventor: Jerome Zeldis
  • Publication number: 20060165649
    Abstract: Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agent is capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of MPD. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: April 13, 2003
    Publication date: July 27, 2006
    Inventor: Jerome Zeldis
  • Publication number: 20060147416
    Abstract: Methods of treating, preventing and/or managing a myelodysplastic syndrome are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or blood or cells for transplantation therapy. Specific second active ingredients are capable of affecting or improving blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Application
    Filed: April 13, 2003
    Publication date: July 6, 2006
    Applicant: Celgene Corporation
    Inventor: Jerome Zeldis